Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella Stuart, R. H. Shaw, Xinxue Liu, Melanie Greenland, Parvinder K. Aley, Nick Andrews, J. Claire Cameron, Sue Charlton, Elizabeth Clutterbuck, Andrea M. Collins, Tom Darton, Tanya Dinesh, C.J. Duncan, Anna England, Saul N. Faust, Daniela M. Ferreira, Adam Finn, Anna L. Goodman, Christopher Green, Bassam Hallis, Paul T. Heath, Helen Hill, Bryn Horsington, Teresa Lambe, Rajeka Lazarus, Vincenzo Libri, Patrick Lillie, Yama F Mujadidi, Ruth Payne, Emma L Plested, Samuel Provstgaard-Morys, Maheshi Ramasamy, Mary Ramsay, Robert C. Read, Hannah Robinson, Gavin Screaton, Nisha Singh, David P. J. Turner, Paul Turner, Iason Vichos, Rachel White, Jonathan S Nguyen-Van-Tam, Matthew D. Snape